Heather H. Cheng

Also affiliated with Fred Hutch Cancer Center, DC Cancer Consortium

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile

0.476Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2

JCO Precision Oncology(2024)10.1200/po.23.00407

Top 40%

0.476DataRank

Top 40%10 citations

Alain C. Mita, Zihan Wei, Heather H. Cheng, Edith P. Mitchell, John J. Wright +16 more

Papers

Driven by 37 papers — median percentile 60. Top paper: “Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W”.

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

Journal of Clinical Oncology(2020)10.1200/jco.19.02630

N/A

4.7DataRank · unranked

179 citations

Fangxin Hong, Christos Vaklavas, Heather H. Cheng, Peter S. Hammerman, Edith P. Mitchell +17 more

Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing

Contemporary Clinical Trials(2022)10.1016/j.cct.2022.106821

N/A

0.673DataRank · unranked

13 citations

Heather H. Cheng, Amy Leader, Laura Gross, Tatiana Sanchez Nolasco, Nataliya Byrne +21 more

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2

JCO Precision Oncology(2024)10.1200/po.23.00407

Top 40%

0.476DataRank

Top 40%10 citations

Alain C. Mita, Zihan Wei, Heather H. Cheng, Edith P. Mitchell, John J. Wright +16 more

Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Cancer Research Communications(2023)10.1158/2767-9764.crc-23-0446

N/A

0.414DataRank · unranked

8 citations

Natalie Slopen, Hannah D. McManus, Karen A. Autio, Alicia K. Morgans, Lawrence McSwain +24 more

Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies

Cancer Research Communications(2025)10.1158/2767-9764.crc-25-0069

N/A

0.288DataRank · unranked

5 citations

Roman Gulati, Erolcan Sayar, Radhika A. Patel, Pushpa Itagi, Helen Richards +25 more

Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort study

Urologic Oncology Seminars and Original Investigations(2025)10.1016/j.urolonc.2025.07.024

N/A

0.165DataRank · unranked

2 citations

Elizabeth Koehne, Jenna Voutsinas, Leonidas Nikolaos Diamantopoulos, Dimitrios Makrakis, Petros Grivas +19 more

Treatment response comparisons between ATM and BRCA2 germline carriers for mCRPC.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.63

N/A

0DataRank · unranked

2 citations

Catherine H. Marshall, Rebeca Lozano, Petros Grivas, Celestia S. Higano, Tamara L. Lotan +11 more

Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of androgen deprivation (AD) +/- cixutumumab, in new metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.106

N/A

0DataRank · unranked

0 citations

Mai T. Duong, Catherine M. Tangen, Neeraj Agarwal, Heather H. Cheng, Nicholas J. Vogelzang +5 more

Molecular Subtyping in the Neoadjuvant Setting in Prostate Cancer: Envisioning the Possibilities

European Urology(2021)10.1016/j.eururo.2021.04.029

N/A

0DataRank · unranked

2 citations

Heather H. Cheng

Genetic Contribution to Metastatic Prostate Cancer

Urologic Clinics of North America(2021)10.1016/j.ucl.2021.03.005

N/A

0DataRank · unranked

3 citations

Elias Obeid, Heather H. Cheng, Alexandra Sokolova

Differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5040

N/A

0DataRank · unranked

0 citations

Emily Nizialek, Jacob E. Berchuck, Panagiotis J. Vlachostergios, Ryan Ashkar, Alexandra Sokolova +14 more

Germline genetics of prostate cancer

The Prostate(2022)10.1002/pros.24340

N/A

0DataRank · unranked

28 citations

Heather H. Cheng, Hiba Khan

Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer

Prostate Cancer and Prostatic Diseases(2022)10.1038/s41391-022-00636-0

N/A

0DataRank · unranked

23 citations

Roman Gulati, Todd Yezefski, Heather H. Cheng, Elahe A. Mostaghel, Michael C. Haffner +17 more

Rates of germline genetic testing and DNA damage response mutations found through population-based recruitment of men with incident metastatic prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.10501

N/A

0DataRank · unranked

3 citations

Risa Liang Wong, Burcu F. Darst, Colin C. Pritchard, Peter S. Nelson, Janet L. Stanford +3 more

Longitudinal screening for depression and anxiety in prostate cancer (PC) and association with disease and treatment factors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5023

N/A

0DataRank · unranked

1 citations

Heather H. Cheng, Jesse R. Fann, James Hnida, Marty Chakoian, Yael Schenker +3 more

Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study

Clinical Genitourinary Cancer(2023)10.1016/j.clgc.2023.05.014

N/A

0DataRank · unranked

33 citations

Funda Vakar‐Lopez, Martine P. Roudier, José M. Garcia, Sonali Arora, Heather H. Cheng +10 more

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

European Urology Oncology(2023)10.1016/j.euo.2023.11.014

N/A

0DataRank · unranked

18 citations

Fadi Taza, Navonil De Sarkar, Alok K. Tewari, Syed Arsalan Ahmed Naqvi, Irbaz Bin Riaz +32 more

Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US

Quality of Life Research(2023)10.1007/s11136-023-03468-0

N/A

0DataRank · unranked

9 citations

Natalie Slopen, Karen A. Autio, Alicia K. Morgans, Lawrence McSwain, Pedro C. Barata +18 more

PSMA expression and response to 177Lu-PSMA-617 (LuPSMA) in men with vs. without DNA damage repair (DDR) mutations.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5055

N/A

0DataRank · unranked

6 citations

George Mo, Michael C. Haffner, Colm Morrissey, Gavin Ha, Evan Y. Yu +9 more

Assessment of Cell Surface Targets in Metastatic Prostate Cancer: Expression Landscape and Molecular Correlates

Research Square(2023)10.21203/rs.3.rs-3745991/v1

N/A

0DataRank · unranked

4 citations

Azra Ajkunic, Erolcan Sayar, Martine P. Roudier, Radhika A. Patel, Ilsa M. Coleman +22 more

Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5074

N/A

0DataRank · unranked

2 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Yeonjung Jo, Andrea Harzstark +15 more

Final results of a pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the homologous recombination DNA repair pathway.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5054

N/A

0DataRank · unranked

2 citations

Makayla DeJong, Evan Y. Yu, Roman Gulati, Matthew B. Rettig, Peter S. Nelson +4 more

Inherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.390

N/A

0DataRank · unranked

1 citations

Barış Türkbey, Peter L. Choyke, Katherine Lee-Wisdom, Yolanda McKinney, Robert Sidlow +10 more

Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates

npj Precision Oncology(2024)10.1038/s41698-024-00599-6

N/A

0DataRank · unranked

32 citations

Erolcan Sayar, Martine P. Roudier, Radhika A. Patel, Ilsa M. Coleman, Navonil De Sarkar +24 more

Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177Lu-PSMA-617: A Retrospective Multicenter Cohort Study

JCO Precision Oncology(2024)10.1200/po.23.00634

N/A

0DataRank · unranked

14 citations

George Mo, Abuzar Moradi Tuchayi, Laura Graham, Roman Gulati, Colin C. Pritchard +13 more

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

European Urology Oncology(2024)10.1016/j.euo.2024.03.001

N/A

0DataRank · unranked

9 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Sam Callis, Yeonjung Jo +17 more

Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer

European Urology Oncology(2024)10.1016/j.euo.2024.11.011

N/A

0DataRank · unranked

8 citations

Wassim Abida, Emmanuel S. Antonarakis, Alan H. Bryce, Elena Castro, Heather H. Cheng +3 more

Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD Trial

European Urology(2024)10.1016/j.eururo.2024.05.025

N/A

0DataRank · unranked

3 citations

Makayla DeJong, Matthew B. Rettig, Evan Y. Yu, Roman Gulati, Michael T. Schweizer +5 more

Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer

Journal of Clinical Investigation(2025)10.1172/jci186599

N/A

0DataRank · unranked

10 citations

Roman Gulati, Erolcan Sayar, Radhika A. Patel, Micah Tratt, Helen Richards +40 more

Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes

European Urology Oncology(2025)10.1016/j.euo.2025.01.002

N/A

0DataRank · unranked

6 citations

Abuzar Moradi Tuchayi, Soon Khai Low, Ali T. Arafa, Laura Graham, Roman Gulati +15 more

Results from a Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with DNA Homologous Recombination Repair Deficiency

European Urology Oncology(2025)10.1016/j.euo.2025.04.026

N/A

0DataRank · unranked

2 citations

Heather H. Cheng, Roman Gulati, Michael T. Schweizer, Aaron Lin, Todd Yezefski +7 more

Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations

European Urology Focus(2025)10.1016/j.euf.2025.11.011

N/A

0DataRank · unranked

0 citations

Sam Callis, Evan Y. Yu, Scott E. Delacroix, Alexandra Sokolova, Catherine M. Tangen +4 more

Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference

JAMA Oncology(2020)10.1001/jamaoncol.2020.5161

N/A

0DataRank · unranked

160 citations

Eric Q. Konnick, Michael T. Schweizer, Alexandra Sokolova, Petros Grivas, Heather H. Cheng +7 more

Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program

Clinical Genitourinary Cancer(2020)10.1016/j.clgc.2020.10.002

N/A

0DataRank · unranked

19 citations

Sarah K. Holt, Ali Raza Khaki, Rishi Sekar, Adam J. Gadzinski, Yaw A. Nyame +17 more

Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer

PLoS ONE(2020)10.1371/journal.pone.0239686

N/A

0DataRank · unranked

10 citations

Rigo I. Acevedo, Daniel M. Lim, Roman Gulati, Agnes Gawne, Alexandra Sokolova +6 more

Implementation of systematic germline genetic testing (GT) for metastatic prostate cancer (mPC) patients at the Puget Sound VA prostate oncology clinic.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1578

N/A

0DataRank · unranked

3 citations

Akemi N. Miyamoto, Darren Pouv, Heather H. Cheng, Bruce Montgomery, Alexandra Sokolova

A pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the BRCA1/2 pathway.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.127

N/A

0DataRank · unranked

2 citations

Makayla DeJong, Evan Y. Yu, Roman Gulati, Matthew B. Rettig, Celestia S. Higano +4 more

Heather H. Cheng

Indexed papers

Top data-sharing exemplar

Papers